Zoetis has received a United States Department of Agriculture (USDA) licence for Cytopoint Plus, a next-generation monoclonal antibody designed to provide up to 75 days of relief from allergic itch in dogs with allergic dermatitis. The product extends the dosing interval of the company’s established Cytopoint therapy and strengthens its position in the veterinary dermatology biologics market.
Zoetis Inc. (NYSE: ZTS) announced on 11 November 2026 that the USDA has licensed Cytopoint Plus for the treatment of allergic dermatitis in dogs. The company describes it as the first and only USDA-licensed next-generation monoclonal antibody for canine allergic dermatitis designed to provide 75 days of itch relief following a single veterinary-administered injection.
Zoetis stock price, however, remained indifferent to this failry important news as corporate eranings of Zoetis have remained under pressure – driven largely by increased competition in Derma space and with Zoetis steadily losing market share.
The development represents a significant product-life-cycle extension for Zoetis’ canine dermatology portfolio. Cytopoint Plus retains the established interleukin-31 (IL-31) targeted mechanism of Cytopoint while offering a substantially longer treatment interval.
For veterinary practitioners, the longer interval could reduce the frequency of clinic visits and simplify the long-term management of dogs affected by chronic allergic skin disease.
A longer-acting approach to IL-31 inhibition
Cytopoint Plus is a monoclonal antibody (mAb) targeting interleukin-31, a cytokine involved in transmitting itch signals in dogs.
IL-31 plays an important role in the neuroimmune pathways associated with allergic dermatitis and canine atopic dermatitis. When inflammatory and immune pathways stimulate IL-31 signalling, dogs may develop persistent pruritus, scratching, licking, chewing and skin trauma. By binding and neutralising IL-31, Cytopoint Plus is designed to interrupt this itch-signalling pathway.
Unlike broad immunosuppressive approaches, the treatment targets a specific cytokine involved in allergic itch. This targeted mechanism has been the foundation of Zoetis’ Cytopoint franchise.
The new formulation has been developed to extend the duration of biological activity, allowing a longer interval between injections.
75 days versus four to eight weeks: the dosing distinction
The principal commercial and clinical differentiation is the duration of action.
Product |
Active approach |
Company-stated dosing interval |
|---|---|---|
Cytopoint (lokivetmab) |
Monoclonal antibody targeting IL-31 |
4–8 weeks |
Cytopoint Plus |
Next-generation, long-acting monoclonal antibody targeting IL-31 |
75 days |
Cytopoint Plus is administered subcutaneously by a veterinary healthcare professional. The company states that a single injection is designed to provide 75 days of relief, equivalent to approximately 10.7 weeks. This is a meaningful extension over the original Cytopoint schedule.
The practical value is particularly relevant for dogs requiring ongoing management, owners who face challenges attending frequent veterinary appointments and practices managing large caseloads of dermatology patients. The longer interval may also improve continuity of treatment by reducing the number of scheduled injection visits.
Clinical evidence: onset within one day and efficacy through Day 75
According to Zoetis, studies supporting USDA licensure demonstrated the onset of itch relief within one day and sustained efficacy through Day 75. The company also reports that reduced itch scores compared with controls were observed through Day 90 in some dogs.
The distinction between these findings is important: Day 75 represents the stated treatment duration, while observations through Day 90 in some animals should not be interpreted as a universal 90-day dosing interval. Zoetis reports that Cytopoint Plus demonstrated a safety profile similar to Cytopoint in the studies supporting approval.
Veterinarians will need to review the approved product information, including contraindications, precautions, adverse-event information and dosing instructions, before incorporating the product into clinical practice.
Why canine allergic dermatitis is an important veterinary market
Allergic dermatitis is a major reason for veterinary consultations in companion-animal practice. The condition can involve persistent pruritus, recurrent skin inflammation, secondary bacterial or yeast infections, self-trauma and reduced quality of life. Management frequently requires a multimodal approach, which may include:
-
Identification and management of relevant environmental or food allergens.
-
Control of secondary bacterial and fungal infections.
-
Parasite prevention and treatment.
-
Skin-barrier support and topical therapy.
-
Anti-pruritic medication.
-
Long-term monitoring and reassessment.
The ability to control itch is central to improving patient comfort and reducing the cycle of scratching, inflammation and skin damage.
A long-acting injectable therapy offers a different management option from daily oral treatment or more frequently administered injections. It does not, however, eliminate the need to identify underlying allergic triggers or manage secondary infections.
Strategic significance for Zoetis
Cytopoint Plus expands a portfolio that already includes Cytopoint, Apoquel (oclacitinib tablets) and Apoquel Chewable. These products give Zoetis a range of options across injectable and oral approaches to canine allergic itch. From a product-strategy perspective, the launch is significant for several reasons.
1. Franchise extension: The new product builds on the established Cytopoint mechanism and brand recognition rather than introducing an entirely unrelated therapeutic pathway.
2. Longer treatment interval: A 75-day interval offers a differentiated proposition in the veterinary biologics market.
3. Veterinary practice engagement: Longer-acting therapies can strengthen the relationship between dermatology patients and veterinary practices through planned treatment and follow-up.
4. Treatment adherence: Fewer scheduled injection visits may reduce logistical barriers for owners, although individual treatment response and veterinary judgement remain important.
5. Biologics portfolio depth: The product reinforces Zoetis’ investment in targeted veterinary biologics and companion-animal therapeutics.
Competitive implications for veterinary dermatology
The canine dermatology market includes conventional anti-inflammatory therapies, targeted oral drugs, monoclonal antibodies, topical treatments and allergen-specific immunotherapy.
The competitive differentiation of Cytopoint Plus is not simply the IL-31 mechanism, which is already established through Cytopoint. It is the combination of targeted cytokine inhibition and a longer stated duration of action. Competitors will increasingly need to demonstrate value through:
-
Speed of itch reduction.
-
Duration of clinical response.
-
Safety and tolerability.
-
Convenience of administration.
-
Effect on quality of life.
-
Cost per treatment period.
-
Long-term management outcomes.
For veterinary clinics, the relevant economic comparison will be total treatment cost and clinical benefit over time, not merely the price per injection.
Regulatory and international market considerations
The announcement concerns USDA licensure in the United States. It should not be interpreted as automatic approval in other countries.
Availability in markets such as the United Kingdom, European Union, India and Australia will depend on the relevant national or regional regulatory authorisation, product registration and commercial launch plans.
For the Indian companion-animal market, long-acting dermatology biologics could be commercially relevant, particularly in urban practices managing chronic allergic skin disease. However, local registration, price positioning, cold-chain and distribution requirements will determine accessibility.
Outlook
Cytopoint Plus represents a notable development in canine dermatology, extending the treatment interval of a targeted anti-IL-31 monoclonal antibody to 75 days. The product’s commercial success will depend on veterinary adoption, price positioning, demonstrated real-world duration of response and the extent to which owners value fewer scheduled injections.
For the animal-health industry, the announcement illustrates the continuing evolution of veterinary therapeutics towards targeted biologics with longer duration of action, improved treatment convenience and differentiated chronic-disease management.
